BeiGene is offering 65.6 million shares at $94.9 to $111.6 apiece.
Bloomberg reports that cancer drug developer BeiGene Ltd., is eyeing to raise as much as $7b (US$933m) in a secondary Hong Kong listing after making its debut in New York two years earlier.
The biotech firm is offering a total of 65.6 million shares priced at $94.9 to $111.6 apiece with Baker Bros Advisors, Hillhouse Capital Management, GIC Private Ltd. and Ally Bridge agreeing to buy 19.8 million shares as cornerstone investors.
Proceeds from the share sale will go into research and commercialisation of three developing drugs and expansion of the company’s portfolio and general working capital, according to a prospectus filed by the company.
At least 16 biotech firms are lining up to pursue IPOs in Hong Kong following sweeping market reforms allowing biotech firms with no track record of profitability to list.
Here’s more from Bloomberg:
Do you know more about this story? Contact us anonymously through this link.